THRU ONLINE FILING

August 13, 2026

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Dear Sirs,

Re : Outcome of Board Meeting held on 13th August, 2026

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith our Standalone and Consolidated Unaudited Financial Results along with its limited review reports by the Company's Auditors for the 1st Quarter ended 30th June, 2026 of the financial year 2026-27, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai.

We are also enclosing herewith a press release issued by the Company in respect of its Q1 FY27 unaudited financial Results.

Kindly note that the Board meeting started at 12.00 noon and concluded at 1.30 p.m.

Thanking you.

Yours faithfully
For Ipca Laboratories Limited

HARISH
PANDURANG
KAMATH

Digitally signed by HARISH PANDURANG KAMATH
DN: c=IN, postalCode=400063, st=MAHARASHTRA, street=4204, TOWER B, OBEROI ESQUIRE ,YASHODHAM, MOHAN GOKHALE ROAD ,MUMBAI SUBURBAN,GOREGAON (EAST) ,400063, l=MUMBAI SUBURBAN, o=Personal, serialNumber=72050fb9fadcbc5de6404685117b8355792f5784c7617d9c4cae2a3887d6b809, pseudonym=cfedd4e63f0643129a1780871ed0cb04, 2.5.4.20=3e5648a57390d9262997da3de9051643bfb87e352b111402af42d207e52e25c6, email=HARISH.KAMATH@IPCA.COM, cn=HARISH PANDURANG KAMATH
Date: 2026.08.13 13:32:16 +05'30'

Harish P. Kamath
Corporate Counsel & Company Secretary

Encl: a/a

Ipca Laboratories Ltd.
www.ipca.com
125, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444
E: ipca@ipca.com CIN: L24239MH1949PLC007837

ipca

Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837

Tel:+91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(₹ Crores)

Sr. No.	Particulars	Quarter Ended			Year Ended
		June 30, 2026 Unaudited	March 31, 2026 Unaudited (Note 6)	June 30, 2025 Unaudited	March 31, 2026 Audited
I	Revenue from operations	2,119.24	1,814.35	1,746.90	7,336.75
II	Other Income	17.42	29.88	25.02	94.64
III	**Total Income (I+II)**	**2,136.66**	**1,844.23**	**1,771.92**	**7,431.39**
IV	Expenses				
	a) Cost of materials consumed	445.76	406.27	395.59	1,568.33
	b) Purchases of stock-in-trade	110.75	85.03	84.11	348.51
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(16.10)	(35.51)	(31.81)	(60.06)
	d) Employee benefits expense	467.32	413.53	409.91	1,655.90
	e) Finance costs	5.04	10.48	12.06	43.51
	f) Depreciation and amortisation expense	74.61	70.31	63.13	268.87
	g) Other expenses	533.87	513.85	482.18	2,043.78
	Total Expenses (IV)	**1,621.25**	**1,463.96**	**1,415.17**	**5,868.84**
V	**Profit before exceptional items and tax (III-IV)**	**515.41**	**380.27**	**356.75**	**1,562.55**
VI	Exceptional items : (Income) / expenses (Refer note No.4)	-	30.42	-	30.42
VII	**Profit before tax (V-VI)**	**515.41**	**349.85**	**356.75**	**1,532.13**
VIII	Tax Expense				
	-Current tax	130.43	97.24	92.66	405.25
	-Short / (Excess) provision of earlier years	(0.31)	(3.13)	-	(3.13)
	-Deferred tax liability / (asset)	12.00	(6.55)	2.05	(2.51)
IX	**Profit for the period from continuing operations (VII-VIII)**	**373.29**	**262.29**	**262.04**	**1,132.52**
X	**Other Comprehensive Income**				
	A) Items that will not be reclassified to profit or loss				
	- Actuarial gain/(loss)	(18.14)	5.14	(2.30)	4.60
	Tax effects thereon	4.46	(1.39)	0.59	(1.25)
	- Fair value change through Other Comprehensive Income	-	1.24	-	1.24
	Tax effects thereon	-	-	-	-
	B) Items that will be reclassified to profit or loss				
	- Exchange difference in translating the financial statement of foreign operation	0.11	1.36	(0.25)	1.86
	Tax effects thereon	(0.03)	(0.37)	0.07	(0.50)
	Other Comprehensive Income / (Loss) for the period net of tax (X)	**(13.60)**	**5.98**	**(1.89)**	**5.95**
XI	**Total Comprehensive Income for the period (IX+X)**	**359.69**	**268.27**	**260.15**	**1,138.47**
XII	Paid-up equity share capital (Face value of ₹ 1/- each)	25.37	25.37	25.37	25.37
XIII	Other Equity	-	-	-	7,953.98
XIV	Net Worth	-	-	-	7,979.35
XV	Earnings per share (of ₹ 1/- each) (Not annualised):				
	Basic / Diluted (Before Exceptional items) (₹)	14.71	11.54	10.33	45.84
	Basic / Diluted (After Exceptional items) (₹)	14.71	10.34	10.33	44.64

STAMPED FOR IDENTIFICATION · N V C ASSOCIATES LLP · Chartered Accountants · MUMBAI

Ipca Laboratories Limited

Notes:

1 The above unaudited standalone financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors at their meeting held on August 13, 2026.

2 The Statutory Auditors of the Company have carried out Limited Review of the unaudited standalone financial results and have issued an unmodified audit report thereon.

3 The above financial results are prepared in accordance with the Indian Accounting Standards (IND-AS) as prescribed under Section 133 of the Companies Act, 2013 and are in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 (as Amended).

4 Exceptional items :

(₹ crores)

Sr. No.	Particulars	Quarter Ended			Year Ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
a	Impact of new Labour Codes	-	30.42	-	30.42

Disclosure on above:

a Impact of new Labour Codes

On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to gratuity and leave. The Company assessed the financial implications of these changes which has resulted in increase in gratuity and leave liability arising out of past service cost by ₹ 30.42 crores for the year ended March 31, 2026. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this amount as "Impact of new Labour Codes" under "Exceptional Item" in the Statement of Profit and Loss for the year ended March 31, 2026.

5 At the meeting of the Board of Directors of the Company held on June 26, 2026, it was resolved to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with the Company, subject to necessary consents/approvals. The appointed date for this amalgamation is April 1, 2026. However, pending consents/approvals, no effect for this amalgamation has been given in the unaudited financial results.

6 The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year 2025-26 and the published year to date unaudited figures upto December 31, 2025, which were subjected to limited review.

7 The Company has only one operating segment viz. 'Pharmaceuticals'.

8 Figures of the previous period have been regrouped to conform to the figures of the current period's classification wherever necessary.

By Order of the Board
For **Ipca Laboratories Limited**

Ipca Laboratories Limited

Premchand Godha
Executive Chairman
(DIN 00012691)

Place : Mumbai,
Date : August 13, 2026

STAMPED FOR IDENTIFICATION
N V C & ASSOCIATES LLP
MUMBAI
Chartered Accountants

Independent Auditor's Review Report on Standalone Unaudited Financial Results for the quarter ended June 30, 2026, of Ipca Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as Amended)

To,
The Board of Directors of
Ipca Laboratories Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ("the Statement") of Ipca Laboratories Limited ("the Company") for the quarter ended June 30, 2026, being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time (The Listing Regulations).

2. **Management's responsibility**

   The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind-AS 34) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion in our report on this Statement of standalone unaudited financial results based on our review.

3. **Auditor's Responsibility**

   We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

N V C & Associates LLP Mumbai Chartered Accountants

N V C & Associates LLP
Chartered Accountants
903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email : nvc@nvc.in LLPIN - ACM-9656

4. Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards as specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Other Matters

Attention is drawn to the fact that the figures for the three months ended March 31, 2026, as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full financial year 2025-26 and year-to-date reviewed figures up to the December 31, 2025.

For N V C & Associates LLP
Chartered Accountants
Firm Registration No. 106971W/W101085

N Jayendran
Partner
M. No. 040441
Mumbai Dated: August 13, 2026
UDIN: 26040441JRFWAJ6862

N V C & Associates LLP Mumbai Chartered Accountants

Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837

Tel:+91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

ipca

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(₹ Crores)

Sr. No.	Particulars	Quarter Ended			Year Ended
		Jun 30, 2026 Unaudited	Mar 31, 2026 Unaudited (Note 8)	Jun 30, 2025 Unaudited	Mar 31, 2026 Audited
I	Revenue from Operations	2,788.10	2,388.48	2,308.85	9,646.33
II	Other Income	25.26	93.74	32.66	174.45
III	**Total Income (I+II)**	**2,813.36**	**2,482.22**	**2,341.51**	**9,820.78**
IV	Expenses :				
	a) Cost of materials consumed	638.14	592.60	617.10	2,344.01
	b) Purchases of stock-in-trade	140.69	149.22	126.74	532.62
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	18.52	(50.20)	(52.28)	(53.91)
	d) Employee benefits expense	601.56	533.00	543.17	2,160.20
	e) Finance costs	11.88	20.20	18.51	75.94
	f) Depreciation and amortisation expense	110.81	107.14	100.06	418.12
	g) Other expenses	719.68	679.99	657.70	2,684.85
	Total Expenses (IV)	**2,241.28**	**2,031.95**	**2,011.00**	**8,161.83**
V	**Profit before exceptional items & tax (III - IV)**	**572.08**	**450.27**	**330.51**	**1,658.95**
VI	Exceptional items: (Income) / expenses (Refer note No.4)	-	45.82	-	86.43
VII	**Profit before tax (V - VI)**	**572.08**	**404.45**	**330.51**	**1,572.52**
VIII	Tax Expense				
	-Current tax	133.21	105.17	95.34	420.63
	-Short / (Excess) provision of earlier years	(0.31)	(3.24)	0.44	(2.80)
	-Deferred tax liability / (asset) / (liability reversal)	16.37	(6.88)	0.31	(36.68)
IX	**Profit for the period before share of profit / (loss) of associates & joint venture (VII-VIII)**	**422.81**	**309.40**	**234.42**	**1,191.37**
X	Add Share of Profit / (less loss) of associates & joint venture (net of tax)	1.46	(2.71)	(1.53)	(7.59)
XI	**Profit for the period from continuing operations before non - controlling interest**	**424.27**	**306.69**	**232.89**	**1,183.78**
XII	Less profit / (add loss) atributable to non-controlling interest	22.38	7.62	(0.32)	42.66
XIII	**Profit for the period attributable to owners of the Company (XI - XII)**	**401.89**	**299.07**	**233.21**	**1,141.12**
XIV	**Other Comprehensive Income (OCI)**				
	A. (i) Items that will not be reclassified to profit or loss				
	Actuarial gain / (loss)	(17.86)	8.65	2.57	14.68
	Tax effect thereon	4.39	(2.25)	0.59	(3.78)
	Fair Value change through Other comprehensive income	-	1.24	-	1.24
	Tax effect thereon	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss				
	Exchange difference in translating the financial statement of foreign operation	(6.58)	19.85	1.72	30.92
	Tax effect thereon	(0.03)	(0.37)	0.07	(0.50)
	C. Share of OCI from investment in associates	-	0.21	-	0.20
	Other Comprehensive Income / (Loss) for the period, net of tax (XIV)	**(20.08)**	**27.33**	**4.95**	**42.76**
XV	**Total Comprehensive Income for the period (XI + XIV)**	**404.19**	**334.02**	**237.84**	**1,226.54**
	Profit after tax attributable to				
	Owners of the parent	401.89	299.07	233.21	1,141.12
	Non-controlling interest - profit / (loss)	22.38	7.62	(0.32)	42.66
		424.27	**306.69**	**232.89**	**1,183.78**
	Other Comprehensive Income for the period attributable to :				
	Owners of the parent	(18.63)	22.99	3.51	37.10
	Non-controlling interest - profit / (loss)	(1.45)	4.34	1.44	5.66
		(20.08)	**27.33**	**4.95**	**42.76**
	Total Comprehensive Income for the period attributable to :				
	Owners of the parent	383.26	322.06	236.72	1,178.22
	Non-controlling interest - profit / (loss)	20.93	11.96	1.12	48.32
		404.19	**334.02**	**237.84**	**1,226.54**
XVI	Paid-up equity share capital (Face value of ₹ 1/- each)	25.37	25.37	25.37	25.37
XVII	Other Equity	-	-	-	8,038.44
XVIII	Net Worth	-	-	-	8,063.81
XIX	Earning per equity share (of ₹ 1/- each) (Not annualised):				
	Basic / Diluted (Before Exceptional items) (₹)	15.84	13.31	9.19	46.94
	Basic / Diluted (After Exceptional items) (₹)	15.84	11.79	9.19	44.98

STAMPED FOR IDENTIFICATION NVC & ASSOCIATES LLP Chartered Accountants MUMBAI

Ipca Laboratories Limited

Notes:

1 These consolidated financial results relate to Ipca Laboratories Limited (the 'Company'), its Subsidiaries (together the 'Group'), Joint Venture and Associates and are prepared by applying Ind AS 110 - "Consolidated Financial Statements" and Ind AS 28 - "Investments in Associates and Joint Ventures.

2 The above consolidated financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on August 13, 2026. The Statutory auditors of the Company have carried out Limited Review of the unaudited consolidated financial results and have issued unmodified report thereon.

3 The above financial results are prepared in accordance with the Indian Accounting Standards (IND-AS) as prescribed under Section 133 of the Companies Act, 2013 and are in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 (as Amended).

4 Exceptional items :

(₹ crores)

Sr. No.	Particulars	Quarter Ended			Year Ended
		Jun 30, 2026	Mar 31, 2026	Jun 30, 2025	Mar 31, 2026
a.	Interest settlement of Europeon Commission	-	-	-	58.26
b.	Impact of new Labour Codes	-	45.82	-	45.82
c.	Net (gain)/ loss on disposal of land & building	-	-	-	(17.65)
	Total	**-**	**45.82**	**-**	**86.43**

Disclosure on above:

a. Interest settlement of Europeon Commission
During the previous year, In continuation of the pending litigation, Unichem Laboratories Limited and its subsidiary Niche Generics Ltd. ("Niche") has received a demand order dated September 17, 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million (INR 203.89 Crores) and the same is fully settled by Unichem on October 28, 2025 after adjusting the payments of Euro 2.79 million (INR 29.12 Crores) already made by Niche in instalments to EU. In regard to above, Unichem had fully recognised a provision in its books towards payment of fine amounting to Euro 13.96 million (INR 125.62 Crores) towards EU fine during year ended March 31, 2024 and the balance amount of INR 58.26 Crores representing the interest is recorded during the previous year under exceptional items by the said Unichem.

b. Impact of new Labour Codes
During the previous year, On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to gratuity and leave. The Holding Company and its subsidiary companies assessed the financial implications of these changes which has resulted in increase in gratuity and leave liability arising out of past service cost by ₹ 45.82 crores for the year ended March 31, 2026. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this amount as "Impact of new Labour Codes" under "Exceptional Item" in the Statement of Profit and Loss for the year ended March 31, 2026.

c. Net (gain)/ loss on disposal of land & building
During the previous year, the Unichem Laboratories Limited has entered into a deed of conveyance dated 9th October 2025 with Lodha Developers Limited (formerly known as "Macrotech Developers Limited") for sale of freehold land and building situated at Prabhat Estate, off S.V. Road, Jogeshwari (West), Mumbai 400102 at an agreed consideration of ₹ 279 crores resulting in a gain (net of related expenses) of ₹ 17.65 crores in consolidated result, which has been recorded as an exceptional item.

5 During the previous year, other income includes an amount of ₹ 60.04 crores Gain on deconsolidation pursuant to sale of Bayshore Pharmaceuticals LLC a subsidiary of the group.

6 At the meeting of the Board of Directors of the Company held on June 26, 2026, it was resolved to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with the Company, subject to necessary consents/approvals. The appointed date for this amalgamation is April 1, 2026. However, pending consents/approvals, no effect for this amalgamation has been given in the unaudited financial results.

7 In accordance with Ind AS-108 "Operating Segments", the operations of the Group are categorised in one segment viz Pharmaceuticals.
The geographic information of the Group's revenues by the Company's country of domicile and other countries is tabulated hereunder:

(₹ crores)

Particulars	Quarter Ended			Year Ended
	Jun 30, 2026	Mar 31, 2026	Jun 30, 2025	Mar 31, 2026
Segment Revenue				
- India	1,229.21	1,019.83	1,083.17	4,386.62
- Outside India	1,558.89	1,368.65	1,225.68	5,259.71
Total	**2,788.10**	**2,388.48**	**2,308.85**	**9,646.33**

The geographic information of the Non-current assets "outside India" is less than 10% of the total Non-current assets of the Group and therefore, not disclosed separately.

8 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year 2025-26, and the published year to date unaudited figures upto December 31, 2025, which were subjected to limited review.

9 Figures for the previous period have been regrouped to confirm to the figures of the current period's classification wherever necessary.

By Order of the Board
For **Ipca Laboratories Limited**

Premchand Godha
Executive Chairman
(DIN 00012691)

Place : Mumbai
Date : August 13, 2026

STAMPED FOR IDENTIFICATION
N V C & ASSOCIATES LLP
MUMBAI
Chartered Accountants

Ipca Laboratories Limited

N V C & Associates LLP
Chartered Accountants
903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email : nvc@nvc.in LLPIN - ACM-9656

Independent Auditor's Review Report on Unaudited Consolidated Financial Results for the quarter ended June 30, 2026, of IPCA Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as Amended)

To,
The Board of Directors of
Ipca Laboratories Limited,

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Ipca Laboratories Limited (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income of its joint ventures and associates for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. **Management's responsibility**

   This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion in our report on this Statement of unaudited consolidated financial results based on our review.

3. **Auditor's Responsibility**

   Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

N V C & Associates LLP Mumbai Chartered Accountants

N V C & Associates LLP
Chartered Accountants

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email : nvc@nvc.in LLPIN - ACM-9656

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

5. The Statement includes unaudited standalone financial results of the following entities:

Sr. No.	Name of the Entities
	IPCA Laboratories Limited - Holding Company
	Subsidiaries
1	Ipca Pharma Nigeria Limited, Nigeria
2	Ipca Laboratories (U.K.) Limited, UK
3	Ipca Pharmaceuticals,Inc (USA)
4	Ipca Pharma (Australia) Pty Limited, Australia
5	Trophic Wellness Private Limited
6	Unichem Laboratories Limited
7	Unichem Laboratories Limited, Ireland
8	Ipca Pharmaceuticals Gmbh
	Step down Subsidiaries
1	Onyx Scientific Limited, UK
2	Ipca Pharma (NZ) Pty Limited, New Zealand
3	Pisgah Labs Inc., USA
5	Niche Generics Limited, United Kingdom
6	Unichem Pharmaceuticals (USA), Inc., USA
7	Unichem SA (Pty) Limited, South Africa
8	Unichem Farmaceutica Do Brasil Ltda, Brazil
9	Unichem (China) Pvt. Ltd.
	Associate
1	Krebs Biochemicals & Industries Limited
	Joint Venture
1	Avik Pharmaceuticals Limited
2	Lyka Labs Limited

N V C & Associates LLP Mumbai Chartered Accountants

N V C & Associates LLP
Chartered Accountants
903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email : nvc@nvc.in LLPIN - ACM-9656

6. Based on our review conducted and procedures performed as stated in paragraph 3 and 4 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. Other Matter

a) We did not review the special purpose consolidated financial results of one subsidiary, whose consolidated financial results reflect total revenue of Rs. 648.23 Crores and net profit after tax of Rs. 38.76 Crores and total comprehensive income of Rs 35.70 Crores for the quarter ended June 30, 2026, before giving effect to elimination of intra-group transactions as considered in the preparation of the consolidated financial results. These special purpose financial statements have been prepared for the purposes of harmonizing accounting policy as followed by parent company for inventory valuation i.e. change the cost formula followed by the subsidiary company from weighted average to First in First out and have been reviewed by other auditors whose report has been furnished to us by the Management and Our conclusion on the statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter.

b) These consolidated financial results also include the Group's share of loss after tax of Rs 0.39 crores and Total Comprehensive loss of Rs 0.39 crores in respect of one associate and one joint venture, for the quarter ended June 30, 2026, as considered in the Statement. These unaudited financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associates and joint venture, are based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.

c) We also did not review the financial results of ten subsidiaries whose financial results reflects, total revenues Rs. 127.58 Crores, net profit after tax of Rs 3.36 Crores and Total Comprehensive loss of Rs 0.72 crores for the quarter ended June 30, 2026, as considered in these financial results. The consolidated financial results also include the Group's share of net profit of Rs 1.89 crores and Total Comprehensive income of Rs 1.89 crores in respect of 1 joint ventures. These financial statements of immaterial subsidiaries and joint venture have been prepared by the management for consolidation purposes and are incorporated in these consolidated financial statements on the basis of the management accounts on which we have not carried out any review procedures. Our conclusion is not modified on this account.

N V C & Associates LLP * Chartered Accountants * Mumbai

N V C & Associates LLP
Chartered Accountants
903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email : nvc@nvc.in LLPIN - ACM-9656

d) Attention is drawn to the fact that the figures for the three months ended March 31, 2026 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full financial year 2025-2026 and year-to-date reviewed figures up to December 31, 2025.

For N V C & Associates LLP
Chartered Accountants
Firm Registration No. 106971W/W101085

N Jayendran
Partner
Membership. No. 040441
Mumbai Dated: August 13, 2026
UDIN: 26040441QPYRYZ4893

N V C & Associates LLP Mumbai Chartered Accountants

PRESS RELEASE

Ipca Laboratories Q1 FY27 Unaudited Financial Results

Mumbai, August 13, 2026 : Ipca Laboratories Limited today announced its unaudited financial results for the first quarter ended 30th June, 2026 of the financial year 2026-27.

Key Financials of Q1 FY27

- Standalone Net total Income up 21% at Rs. 2136.66 crores.
- Consolidated Net total Income up 20% at Rs. 2813.36 crores.
- Indian formulations income up 13% at Rs 1082.12 crores.
- Exports Income up 34% at Rs. 935.39 crores.
- Standalone EBITDA margin (before forex (gain)/loss and other income) @ 26.27% in Q1 FY27 as against @ 23.82% in Q1 FY26.
- Consolidated EBITDA margin (before forex (gain)/loss and other income) @ 22.88% in Q1 FY27 as against @ 18.39% in Q1 FY26.
- Standalone Net Profit at Rs. 373.29 crores up 42%.
- Consolidated Net Profit at Rs. 422.81 crores up 80%.

Standalone Q1 FY27 at a glance			(Rs. Crores)
Particulars	**Q1 FY27**	**Q1 FY26**	**Growth**
Revenue from Operations	2119.24	1746.90	21%
Export Income	935.39	699.76	34%
EBITDA before Forex (gain) / loss and other income	556.82	416.04	34%
Other Income	17.42	25.02	-30%
Forex (gain) / loss	(20.82)	9.12	-
Finance Cost	5.04	12.06	-58%
Depreciation and Amortisation	74.61	63.13	18%
Tax Expense	142.12	94.71	50%
Net Profit after tax	373.29	262.04	42%
Earnings per share of Re. 1/- each (Rs)	14.71	10.33	42%

Ipca Laboratories Limited

Ipca Laboratories Ltd.
www.ipca.com
125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444
E: ipca@ipca.com CIN: L24239MH1949PLC007837

ipca A dose of life

Consolidated Q1 FY27 at a glance			(Rs. Crores)
Particulars	**Q1 FY27**	**Q1 FY26**	**Growth**
Revenue from Operations	2788.10	2308.85	21%
EBITDA before Forex (gain) / loss and other income	637.94	424.58	50%
Other income	25.26	32.66	-23%
Forex (gain) / loss	(31.57)	8.16	-
Finance Cost	11.88	18.51	-36%
Depreciation and Amortisation	110.81	100.06	11%
Tax Expense	149.27	96.09	55%
Profit for the period including share of non – controlling interest but before share of profit / (loss) of associates & joint venture	422.81	234.42	80%
Add share of profit / (less loss) of associates & joint venture	1.46	(1.53)	-
Less profit / (add loss) attributable to non – controlling interest.	22.38	(0.32)	-
Net Profit after tax	401.89	233.21	72%
Earnings per share of Re. 1/- each (Rs.)	15.84	9.19	72%

Q1 FY27 Revenue break-up			(Rs. Crores)
Particulars	**Q1 FY27**	**Q1 FY26**	**Growth**
Formulations			
Domestic	1082.12	961.01	13%
Exports			
Branded	143.27	123.59	16%
Institutional	119.75	57.83	107%
Generics	340.02	268.19	27%
Total Formulations	**1685.16**	**1410.62**	**19%**
APIs			
Domestic	91.37	76.19	20%
Exports	332.35	250.15	33%
Total APIs	**423.72**	**326.34**	**30%**
Other Operating Income	10.36	9.94	4%
Standalone Revenue from Operations	**2119.24**	**1746.90**	**21%**
Revenue from Operations - Subsidiaries	668.86	561.95	19%
Consolidated Revenue from Operations	**2788.10**	2308.85	**21%**
Other Income	25.26	32.66	-23%
Consolidated Net Total Income	**2813.36**	**2341.51**	**20%**

Ipca Laboratories Limited

Ipca Laboratories Ltd.
www.ipca.com
125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444
E: ipca@ipca.com CIN: L24239MH1949PLC007837

About Ipca Laboratories:

Ipca is a fully integrated pharmaceutical company with a strong thrust on exports. Ipca is vertically integrated and produces Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs).

Ipca Laboratories Limited

Premchand Godha
Executive Chairman

Encl: Unaudited Standalone & Consolidated Financial Results

Contact Information:
Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamath@ipca.com or on +91-22- 6210 6050